Validation of the Dutch version of the Edmonton Symptom Assessment System

Frederieke H. van der Baan1 | Josephine J. Koldenhof2 | Ellen J. de Nijs3 | Michael A. Echteld4 | Danielle Zweers2 | Ginette M. Hesselmann5 | Sigrid C. Vervoort5 | Jan B. Vos5 | Everlien de Graaf1 | Petronella O. Witteveen2 | Karijn P. Suijkerbuijk2 | Alexander de Graeff2 | Saskia C. Teunissen1

Content, construct and criterion validity, responsiveness, and cutoff points are shown with prevalences, area under receiver operating characteristic (ROC) curve, Chi-squared test, Wilcoxon signed-rank test, and positive and negative predictive values, respectively.

Results: A total of 3913 patients completed 22,400 USDs. Content validity was confirmed for all added USD items with prevalences of ≥22%. All USD items also present on the DT&PC demonstrated a good criterion validity (ROC >0.8). Construct validity was confirmed for the USD as a whole and for the items dry mouth, dysphagia and well-being ($P < .0001$). USD scores differed significantly for patients when improving or deteriorating on the DT&PC which confirmed responsiveness. Optimal cutoff points (3 or 4) differed per symptom.

Conclusion: The USD is a valid 12-item PROM for the most prevalent symptoms in cancer patients, which has content, criterion, and construct validity, and detects clinically important changes over time, in both curative and palliative phase.

KEYWORDS
Cancer, patient reported outcome measures, quality of life, symptom assessment

Received: 31 January 2020 | Revised: 29 May 2020 | Accepted: 2 June 2020

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Cancer Medicine. 2020;9:6111–6121.
1 | INTRODUCTION

Cancer patients experience many symptoms caused by their disease and/or its treatment which influence health-related quality of life (HRQL). As healthcare professionals tend to underestimate symptoms and family members to over-rate symptoms, symptoms reported by patients themselves are considered to be the most reliable indicators of symptom presence and intensity.1–3

Patient-reported outcome measurement tools (PROMs) improve patient-professional communication, reduction of symptom severity, reinforcement of patient autonomy, and patients’ satisfaction, regardless of the phase of their disease.4–8 Monitoring symptoms can reduce emergency department visits and improve predictions of life expectancy in terminal ill cancer patients.9,10

Worldwide, a frequently used PROM to routinely assess and monitor symptoms in advanced cancer patients without anticancer treatment is the Edmonton Symptom Assessment System (ESAS).11 Since its development in 1991, the ESAS has been validated, translated, and adapted by multiple groups with a focus on advanced cancer inpatients. Reliability (test-retest and inter-rater reliability) and concurrent validity have been studied mostly, using a variety of other instruments to compare the ESAS to. Much less is known about the responsiveness and the cutoff points to distinguish patients with none, mild, moderate, and severe symptom burden.4,12,13

We developed an adapted Dutch version of the ESAS—the Utrecht Symptom Diary (USD)—which aims to support daily management of symptoms across the entire continuum of cancer care. In the last 20 years, the USD has been implemented in daily practice in several hospitals, general practices and hospices in the Netherlands. Moreover, usage of the USD is recommended by the Netherlands Quality Framework for Palliative Care.14

This study analyses the validity and responsiveness of the USD, as well as the cutoff points per symptom to determine the clinical significance of a symptom score.

2 | METHODS

2.1 | Participants

This observational longitudinal cohort comprises all adult cancer patients treated in the University Medical Center (UMC) Utrecht, the Netherlands, who completed at least one USD between August 2012 and July 2019. Within the UMC Utrecht Cancer Center filling out the USD is standard care, which means that each patient during each out-patient treatment and each admission is asked to complete the symptom diary as a basis for tailoring care. However this does apply to patients with impaired cognitive behavior, not being able to read and understand Dutch language. As a result, no USD is available of these patients.

Some participants receive chemotherapy partly in the clinic and partly in the outpatient clinic. This research was not considered subject to the Medical Research Involving Human Subjects Act by the institutional review board of the UMC Utrecht. For each measurement property of the USD, we selected a subgroup of patients from this cohort.

2.2 | Data collection

For the development of the USD, the ESAS items pain, fatigue, nausea, depression, anxiety, drowsiness, lack of appetite, shortness of breath, and feeling of well-being were translated into Dutch. The items sleeping problems, dry mouth, abnormal stool, and dysphagia were added to the USD, based on their high prevalence in patients with incurable cancer.15,16 Drowsiness was later excluded because of ambiguity in the Dutch language.

The 12 items were clustered in two language specific sections starting with “I have...” and “I feel...” The ESAS item well-being was translated as “I feel good” to “I feel very bad” as the last summarizing question. Moreover, patients were able to add symptoms and to assign priority to symptoms which needed attention first, supporting patients’ autonomy. Symptoms were scored on a 0-10 numeric rating scale (NRS), with higher values indicating increasing symptom intensity.

The USD (Appendix A) was offered daily to all inpatients, to assess and monitor their current symptoms and well-being. Outpatients reported on symptoms and well-being experienced since the last visit to the outpatient clinic. In addition, patients were offered the Distress Thermometer and Problem Checklist (DT&PC) at the start of a (new) treatment and when indicated. The Distress Thermometer and Problem Checklist is an internationally accepted and validated PROM recommended for early recognition of symptoms and detection of supportive care needs in cancer patients.17,18 The Distress Thermometer asks patients to score their distress on a 0-10 visual analogue scale (VAS; a higher score indicating more distress). The Problem Checklist includes 35 items distributed over five domains: practical, family/social, emotional, spiritual, and physical problems. Patients score a symptom dichotomously, experiencing the symptom as a problem or not.

Patient characteristics, disease and treatment-related data, and USD and DT&PC scores, were retrospectively collected from the electronic medical records.

2.3 | Statistical analysis

Patient characteristics were summarized with descriptive statistics. Definitions, methods and quality criteria for
the measurement properties of the USD were based on the COSMIN (Consensus-based Standards for the selection of health Measurement INstruments) initiative.\textsuperscript{19,20} Moreover, we analyzed cutoff points to determine the clinical significance of a symptom score. Patients with a missing value for the studied USD item were excluded for analysis for that item. R software for statistical computing and graphics v3.5.1 were used for statistical analysis.\textsuperscript{21}

2.3.1 | Content validity

Content validity is defined as the extent to which the concepts of interest are represented by the USD items\textsuperscript{20}. To study the patient’s perspective on the content, we asked a subgroup of 100 in- and outpatients in a questionnaire: “were the USD symptoms in line with your symptom burden?” A reported relevance by at least 80% of the patients was considered as a sufficient content validity. In addition, prevalence of the symptoms that were added in the USD to the symptoms of the original ESAS\textsuperscript{11} are presented to assess whether these items are relevant for our population.

2.3.2 | Criterion validity

Criterion validity is defined as the degree to which the USD scores are an adequate reflection of a “gold standard.”\textsuperscript{19} In the absence of a gold standard, for this analysis, the DT&PC was considered the reference standard.

For each patient, we selected the first DT&PC completed within 1 day of a USD. The items pain, sleeping problems, nausea, shortness of breath, fatigue, anxiety, and depressed mood are identical on both instruments and were used for the criterion validation. The USD item lack of appetite was compared to “problem with eating” on the DT&PC. The USD item abnormal stool was compared to the DT&PC diarrhea and constipation.

The area under the curve (AUC) of the receiving–operating curve (ROC) was calculated using the USD scores as predictive values and the DT&PC as the reference standard, indicating the “true” condition. An AUC of at least 0.70 was considered positive for the criterion validity.\textsuperscript{22} The corresponding 95% confidence intervals were computed with 2000 stratified bootstrap replicates.\textsuperscript{23}

2.3.3 | Construct validity

Construct validity is defined as the extent to which USD scores are consistent with theoretically derived hypotheses.\textsuperscript{19} Prior to the analyses we formulated one overall hypothesis concerning all USD items and three hypotheses for the items that are not part of the DT&PC, dry mouth, dysphagia, and well-being:

I “The prevalence and intensity of all symptoms will increase with progression of disease.”\textsuperscript{15,24} Inpatients were divided into two disease stages: inpatients receiving chemotherapy, either with curative or palliative intent, and inpatients receiving symptom directed palliation only. Outpatients and patients admitted for other reasons than chemotherapy treatment were excluded, as we could not determine their disease stage with certainty. The first completed USD during the first hospital admission was used to compare symptom prevalence and intensity.

II “Patients using opioids\textsuperscript{25} experience dry mouth more often than patients who do not use opioids.” The first USD of each inpatient was selected, due to the availability of a complete medication list. USD scores for dry mouth were compared in patients using and patients not using opioids.

III “Patients with head and neck cancer (HNC) experience dysphagia more often than patients with other cancer diagnoses.”\textsuperscript{26} The first USD of HNC patients was compared to the first USD of patients with other primary diagnoses.

IV “Patients with pain report poorer well-being than patients without pain.”\textsuperscript{27} For this purpose, we compared well-being on the first USD of all patients reporting a pain score ≥3 with patients reporting a pain score <3.

In the literature, the optimal cutoff point of the ESAS items remains unclear and varies from 2 to 5 for symptom presence and moderate symptom intensity.\textsuperscript{28–30} In previous research, we found that HRQL decreased due to the experience of multiple symptoms with scores <3 at the same time.\textsuperscript{31–33} Therefore, we considered a USD score ≥3 as clinically relevant. For all hypotheses, we compared the prevalence of a clinically relevant symptom (USD score <3 vs ≥3) and intensity (median score) using a chi-squared test and the nonparametric Mann-Whitney $U$ test, respectively. For the USD item well-being, only the intensity was compared, since dichotomization of well-being was not considered to be meaningful.

2.3.4 | Responsiveness

Responsiveness is defined as the ability of the USD to detect change over time, a measure of longitudinal validity.\textsuperscript{19,22} We selected patients with two subsequent DT&PCs completed within 1 day of a USD. Per USD item patients were selected who “improved” (reporting a problem on the first DT&PC and no problem on the second) or “deteriorated” (no problem on the first DT&PC and a problem on
For each USD item, we compared the median USD score at both measurement points, using Wilcoxon signed-rank test.

### 2.3.5 Cutoff points

By using the USD score and the corresponding problem on the DT&PC, the cutoff point on the USD that best discriminates between patients with and without a clinically significant symptom score was assessed. We selected the first DT&PC that was completed within one day of a USD of all patients. For each item, we explored the performance of cutoff points of 2, 3, and 4 in terms of positive predictive value (PPV) and negative predictive value (NPV), predicting for the presence or absence of the corresponding problem on the DT&PC, respectively.

### 3 RESULTS

A total of 3913 unique patients with cancer completed over 22,400 USDs. Patient characteristics at the time of the first available USD are presented in Table 1, for the whole group, by the presence of concurrent DT&PC and by disease stage. The subgroup of patients with a concurrent DT&PC consisted mainly of outpatients (81%). Sixty percent of the patients received chemotherapy as an outpatient. Nearly all patients receiving symptom directed palliation only were admitted to the hospital, with a median stay of 10 days. Data on

| TABLE 1 | Patient characteristics |
|----------|-------------------------|
|          | Total | USD and DT&PC within one day | Chemotherapy (curative and palliative) | Symptom-directed palliation only |
| N = 3913 | N = 1919 | N = 224 |
| Age - mean (SD) | 60.6 (13) | 59.6 (12) | 58.2 (13) | 63.4 (12) |
| Gender male—N (%) | 2197 (56) | 741 (55) | 1027 (54) | 125 (56) |
| Outpatients—N (%) | 1689 (43) | 1101 (81) | 1147 (60) | 2 (1) |
| Inpatients—N (%) | 2215 (57) | 248 (18) | 769 (40) | 222 (99) |
| Missing—N (%) | 9 (<0.1) | 4 (<0.1) | 3 (<0.1) | NA NA |
| Duration admission (days) — median [IQR] | 7 [5-14] | 5 [4-7] | 6 [4-8] | 10 [6-14] |
| Digestive tract | 1232 (31) | 439 (32) | 627 (33) | 105 (47) |
| Bone marrow and lymph nodes | 549 (14) | 66 (5) | 194 (10) | 2 (1) |
| Female genital tract | 370 (9) | 184 (14) | 327 (17) | 25 (11) |
| Head and neck | 322 (8) | 143 (11) | 284 (15) | 11 (5) |
| Central nervous system | 255 (7) | 39 (3) | 60 (3) | 1 (0) |
| Male genital tract | 250 (6) | 107 (8) | 178 (9) | 16 (7) |
| Breast | 245 (6) | 105 (8) | 151 (8) | 20 (9) |
| Skin | 244 (6) | 143 (11) | 24 (1) | 24 (11) |
| Kidney and urinary tract | 180 (5) | 42 (3) | 34 (2) | 10 (4) |
| Lung and mediastinum | 168 (4) | 65 (5) | 11 (1) | 1 (0) |
| Endocrine | 43 (1) | 5 (0) | 9 (0) | 4 (2) |
| Other | 55 (1) | 15 (1) | 20 (1) | 5 (2) |
| ECOG PS, N (%) |          |          |          |          |
| 0-1 | 1430 (37) | 595 (44) | 1024 (53) | 21 (9) |
| 2 | 236 (6) | 60 (4) | 128 (7) | 24 (11) |
| 3-4 | 123 (3) | 8 (1) | 25 (1) | 42 (19) |
| Missing | 2124 (54) | 690 (51) | 742 (39) | 137 (61) |
| Days between PS and USD - median [IQR] | 6 [1-14] | 5 [0-13] | 6 | 1-14] | 5 [1-14] |

Abbreviations: DT&PC, Distress Thermometer and Problem Checklist; ECOG PS, Eastern Cooperative Oncology Group performance score; IQR, interquartile range; NA, not applicable; SD, standard deviation; USD, Utrecht Symptom Diary.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) were available for 46% of patients.

3.1 | Content validity

A total of 100 patients, 72% inpatients and 28% outpatients, completed the study specific questionnaire. 86% answered that the USD items properly represented their symptom burden. The prevalence of sleeping problems, dry mouth, abnormal stool, and dysphagia are shown in Table 2 for the total study population. The prevalence of ≥22% show the importance of these items, confirming content validity of these added USD items.

3.2 | Criterion validity

A total of 1353 patients (35%) completed at least once a USD and DT&PC within 1 day. 82% of the inpatients who filled out a DT&PC completed it on the first admission day and 18% on another day during admission. For all items, the percentage of missing values was ≤3.5%. See Table 3 for results on criterion validity, comparing the USD scores to the dichotomous outcome of the DT&PC. The lowest AUC is 0.8, demonstrating good criterion validation.

3.3 | Construct validity

A total of 1919 patients (49%) completed a USD during chemotherapy, and 224 (6%) when receiving symptom-directed palliation only. Table 4 summarizes symptom prevalence. During chemotherapy every symptom—except for dyspnea—occurred in >10% of the patients. Highest scores were found for fatigue. During the phase of symptom-directed palliation only, every symptom occurred in ≥25%. A median score of ≥3 was found for 8/12 items. Again, fatigue had the highest intensity. Both the prevalence of USD scores ≥3 and the median scores were higher for all symptoms in patients receiving symptom directed palliation only than in patients during chemotherapy. Thus, the first hypothesis, stating that the prevalence and intensity of all symptoms increase with progression of disease, is confirmed, demonstrating the construct validation for all USD symptom items.

As shown in Table 5, hypotheses 2-4 were confirmed, showing construct validity of the items dry mouth, dysphagia, and well-being, respectively.

3.4 | Responsiveness

A total of 293 patients (7%) completed >1 DT&PC and USD within 1 day. The vast majority (>80%) are outpatients as in our clinical setting the DT&PC is mostly offered to outpatients. Table 6 shows median scores (IQR) before and after symptom improvement or deterioration. The measurements were on average 42 days apart [IQR 7-122]. For all items, the median USD score upon improvement is lower on T2 than on T1 and vice versa upon deterioration. For both improvement and deterioration, median change was 3.

3.5 | Cutoff points

Table 7 shows the performance of three different cutoff points (2, 3, and 4) per item on the USD 0-10 NRS. As expected for all items a lower cutoff increases the NPV. For a cutoff point of ≥3, NPV varied from 0.84 (fatigue) to 0.96 (dyspnea) and for a cutoff ≥4 from 0.75 (fatigue) to 0.95 (dyspnea). For both cutoff scores fatigue, pain, and anxiety had the lowest NPV’s.

4 | DISCUSSION

Previous validations of the ESAS have mainly focused on reliability and concurrent validity in advanced cancer inpatients, using a variety of other instruments to compare the ESAS to. Relatively less evidence is available on responsiveness and cutoff points.4,12,13 Our study fills part of this gap, as we show that the USD, a Dutch and adapted version of the ESAS, is a valid PROM for the most prevalent symptoms in cancer patients within all stages of disease. We also show the content validity of the added items to the USD and the ability to detect clinically important changes over time (responsiveness). Finally, we provide information about the clinical consequences of the generally used cutoff points.

### Table 2 | Content validation

| Condition                          | N (%) |
|------------------------------------|-------|
| Sleeping problems (N = 3801)       | 1640 (43) |
| Dry mouth (N = 3497)               | 1491 (43) |
| Abnormal stool (N = 3698)          | 1629 (44) |
| Dysphagia (N = 3485)               | 755 (22) |

Abbreviation: USD, Utrecht Symptom Diary.

4.1 | Content validity

Our results show content validity of all measured items as patients reported them to reflect their symptom burden. The usefulness of our newly added items—sleeping problems, dry mouth, abnormal stool, and dysphagia—is confirmed since they occur in 22%-44% of our population. Adding
items to the ESAS has occurred before but not specifically in cancer patients.\textsuperscript{34,35} Besides synonyms have been used for items such as constipation and sleep-related problems.\textsuperscript{36,37} Although dry mouth is not part of the ESAS, it is part of the MD Anderson Symptom Inventory (MDASI), which also is a validated and frequently used PROM in cancer patients.\textsuperscript{38} The identification of dysphagia as a symptom to predict life expectancy by Teunissen et al\textsuperscript{15} has been endorsed by others\textsuperscript{39}, emphasizing the relevance of including this item.

### 4.2 | Criterion validity

We found a good concurrent criterion validation of the USD items pain, sleeping problems, anorexia, abnormal stool, nausea, dyspnoea, fatigue, anxiety, and depressed mood, using the dichotomous outcome of the DT&PC. This means the USD is a valid instrument to reflect symptom burden at the time of assessment as well as over a previous period of time. Previous studies have investigated concurrent criterion validity of translated and/or modified versions of the ESAS with other PROMs, as reviewed in detail\textsuperscript{4,13}, also concluding that these ESAS versions are valid for symptom assessment in different palliative care settings.\textsuperscript{37,40,41} The strength of our study is that the USD uses a NRS and the DT&PC questions whether a symptom was considered a problem, therefore reflecting the patient’s perspective on symptom scores. Consequently, insight into patients’ personal cutoff point can be obtained. In previous studies, this was not possible since the PROMs used for comparison

| USD and DT&PC (N) | Prevalence on DT&PC (%) | AUC [95% CI] |
|------------------|------------------------|-------------|
| Pain             | 1332                   | 35.2        | 0.91 [0.89-0.93] |
| Sleeping problems| 1329                   | 32.1        | 0.90 [0.88-0.92] |
| Anorexia         | 1323                   | 27.4        | 0.81 [0.79-0.84] |
| Abnormal stool   | 1305                   | 25.4        | 0.89 [0.87-0.91] |
| Nausea           | 1330                   | 13.9        | 0.91 [0.88-0.94] |
| Dyspnea          | 1325                   | 12.1        | 0.93 [0.91-0.95] |
| Fatigue          | 1332                   | 50.5        | 0.91 [0.89-0.92] |
| Anxiety          | 1326                   | 27.8        | 0.87 [0.85-0.89] |
| Depressed mood   | 1316                   | 22.7        | 0.87 [0.85-0.90] |

Abbreviations: AUC, Area under ROC curve; CI, confidence interval; DT&PC, Distress Thermometer and Problem Checklist; USD, Utrecht Symptom Diary.

| Prevalence—N (%) | Symptom directed palliation only | Intensity—median [IQR] | Symptom directed palliation only |
|------------------|----------------------------------|------------------------|----------------------------------|
| USD score ≥3     | Chemotherapy (N = 1919)           | P-value<sub>a</sub>     | Chemotherapy (N = 1919)           | P-value<sub>b</sub>     |
| Pain             | 452 (24)                          | <.0001                 | 1 [0-3]                           | 3 [1-6]                 | <.0001 |
| Sleeping problems| 539 (29)                          | <.0001                 | 1 [0-4]                           | 4 [1-7]                 | <.0001 |
| Dry mouth        | 466 (25)                          | <.0001                 | 0 [0-3]                           | 5 [2-8]                 | <.0001 |
| Dysphagia        | 318 (17)                          | <.0001                 | 0 [0-2]                           | 1 [0-4]                 | <.0001 |
| Anorexia         | 614 (33)                          | <.0001                 | 1 [0-5]                           | 6 [3-8]                 | <.0001 |
| Abnormal stool   | 548 (30)                          | <.0001                 | 1 [0-5]                           | 5 [2-8]                 | <.0001 |
| Nausea           | 232 (12)                          | <.0001                 | 0 [0-1]                           | 0 [0-3]                 | <.0001 |
| Dyspnea          | 141 (8)                           | <.0001                 | 0 [0-1]                           | 1 [0-4]                 | <.0001 |
| Fatigue          | 779 (41)                          | <.0001                 | 3 [0-5]                           | 6 [3-8]                 | <.0001 |
| Anxiety          | 356 (19)                          | <.0001                 | 0 [0-3]                           | 1 [0-5]                 | <.0001 |
| Depressed mood   | 308 (17)                          | <.0001                 | 1 [0-3]                           | 3 [1-6]                 | <.0001 |
| Well-being       | NA                                | NA                     | 1 [0-4]                           | 4 [1-7]                 | <.0001 |

Abbreviations: IQR, inter quartile range; NA, not applicable.

<sup>a</sup>Chi square.
<sup>b</sup>Mann-Whitney U
both utilized measuring scales. Hui and Bruera\textsuperscript{12} reflected on this importance by describing how one patient may consider a score of 6/10 as agonizing while another may find it acceptable.

We used routine clinical data, which may be a limitation of our study. Since we only have information on the DT&PC when it was offered and completed, selection bias may be implied. Second, the DT&PC asks patients to report on symptoms over a time window of a week, whereas the USD captures current symptoms for inpatients and symptoms since last visit for outpatients. In our population, 82% of inpatients completed the USD and DT&PC on the first admission day. This makes it very likely that the symptom burden represents the patient’s situation of the days before the admission as well.

### 4.3 Construct validity

We found a good construct validity on the USD items dry mouth, dysphagia, and well-being. To the best of our knowledge, there is only one other study using hypothesis testing to validate a translated and modified ESAS version in a small convenience sample of 23 cancer patients.\textsuperscript{42} Several groups studied construct validity by investigating correlations between clusters of symptoms, hypothesizing a larger underlying construct measured by the ESAS items.\textsuperscript{12,43} However, we decided to consider each symptom as an independent “construct.” A sum score of all items has been studied\textsuperscript{41,44}, as suggested by Bruera et al\textsuperscript{11} to represent overall symptom distress as a construct. As we question the underlying assumption that low USD scores on multiple

### TABLE 5 Construct validity—Hypotheses 2-4

|                      | N   | USD score ≥3 N (%) | P-value\textsuperscript{a} | Intensity median [IQR] | P-value\textsuperscript{b} |
|----------------------|-----|------------------|--------------------------|------------------------|--------------------------|
| Dry mouth            |     |                  |                          |                        |                          |
| Opioid use           | 537 | 309 (58)         | <.0001                   | 4 [2-7]                | <.0001                   |
| No opioid use        | 1678| 616 (37)         |                          | 2 [0-5]                |                          |
| Dysphagia            |     |                  |                          |                        |                          |
| Head and neck        | 322 | 117 (37)         | <.0001                   | 2 [0-5]                | <.0001                   |
| Other diagnoses      | 3591| 475 (15)         |                          | 0 [0-2]                |                          |
| Well-being           |     |                  |                          |                        |                          |
| Pain score ≥3        | 1402| NA               | NA                       | 5 [3-6]                | <.0001                   |
| Pain score <3        | 2506| NA               | NA                       | 2 [0-4]                |                          |

Abbreviations: IQR, inter quartile range; NA, not applicable.

\textsuperscript{a}Chi square,

\textsuperscript{b}Mann-Whitney U.

### TABLE 6 Responsiveness

| Improvement          | Improvement | Median score [IQR] | P-value\textsuperscript{a} | Deterioration | Median score [IQR] | P-value\textsuperscript{a} |
|----------------------|-------------|-------------------|--------------------------|--------------|-------------------|--------------------------|
|                      | N           | T1                | T2                       | T1           | T2                | T2                       | T1           | T2                | T2                |
| Pain                 | 41          | 3 [2-5]           | 2 [0-3]                  | .0028        | 59                | 0 [0-2]                  | 4 [2-6]      | .0001             |                  |
| Sleeping problems    | 51          | 4 [2-7]           | 1 [0-2]                  | <.0001       | 53                | 0 [0-2]                  | 3 [2-5]      | <.0001             |                  |
| Anorexia             | 45          | 5 [2-7]           | 2 [0-5]                  | .011         | 39                | 1 [0-5]                  | 5 [3-7]      | <.0001             |                  |
| Abnormal stool       |             |                   |                          |              |                   |                          |              |                   |                  |
| Diarrhea             | 23          | 5 [2-6]           | 2 [0-3]                  | .015         | 36                | 1 [0-3]                  | 5 [2-6]      | <.0001             |                  |
| Obstruction          | 26          | 5 [4-6]           | 2 [1-5]                  | .005         | 46                | 0 [0-1]                  | 5 [3-7]      | <.0001             |                  |
| Nausea               | 24          | 3 [2-5]           | 1 [0-2]                  | .00069       | 50                | 0 [0-1]                  | 3 [1-4]      | <.0001             |                  |
| Dyspnea              | 13          | 3 [2-4]           | 0 [0-2]                  | .019         | 28                | 0 [0-0]                  | 3 [2-5]      | <.0001             |                  |
| Fatigue              | 38          | 4 [3-5]           | 2 [1-3]                  | .00016       | 70                | 1 [0-3]                  | 4 [2-5]      | <.0001             |                  |
| Anxiety              | 31          | 3 [2-5]           | 1 [0-2]                  | <.0001       | 35                | 0 [0-2]                  | 3 [2-5]      | <.0001             |                  |
| Depressed mood       | 21          | 4 [3-5]           | 1 [0-3]                  | <.0001       | 42                | 0 [0-1]                  | 3 [2-5]      | <.0001             |                  |

\textsuperscript{a}Wilcoxon test.
symptoms is comparable to a single high symptom score, based on other work of our group\(^3\), we decided not to summarize scores in this study.

### 4.4 Responsiveness

Our results on responsiveness show that the USD is able to detect clinically significant differences over time for all items, as we show that patients who report improvement or deterioration on items of the DT&PC, have lower and higher USD scores at the second time point, respectively.

Paiva et al\(^4\) studied responsiveness of the Brazilian version of the ESAS using an anchor-based method, asking 80 patients to classify after 21 days whether their symptoms were worse, the same or better than experienced during the first visit. Although they found that the median scores of patients who felt better indeed improved, and those of patients who reported a worsened condition were decreased, they could not show responsiveness for all items. Most probably this was caused by their small sample size and a patient population with a low symptom burden.

The strength of our comparison of the USD to a concurrent DT&PC is that we compared USD scores to a reflection by the patients of the symptom as a problem or not, which makes improvement or deterioration of symptoms clinically relevant. We did not find evidence that in- and outpatients score differently on the USD when a symptom improved or deteriorated according to the DT&PC. Moreover, we performed analyses with multiple measures of one individual patient in order to obtain criterion validity, construct validity, and responsiveness data. Patient setting will not likely influence these within-person analyses.

A limitation of our approach is that we do not know which patients remained stable, since reporting a symptom on both T1 and T2 as a problem on the DT&PC does not inform us whether the patient experienced this symptom in the same way at both moments. Consequently, calculating an AUC, which is the measure for responsiveness\(^2\), as well as the minimal clinically important difference for improvement and deterioration was not possible. The latter was studied by Hui et al for the ESAS\(^4\), concluding that for all symptoms the optimal cutoff for improvement was ≥1 point and ≤1 point for deterioration. Though with sensitivities of only 59%-85%, indicating relatively many false negatives, which are patients who actually experienced a symptom change, but are missed with these cutoffs.

### 4.5 Cutoff points

The symptoms of the ESAS with scores of 0, 1-3, 4-6, and 7-10 are generally considered as absent, mild, moderate, and severe, respectively.\(^2,29,47,48\) However, we found that, when using NRS ≥4 as cutoff for moderate symptom burden, except for nausea and dyspnoea, >10% of patients with a score <4 would be misclassified as having “none” or “mild” symptoms, whereas in fact they reported the symptom as a problem. It is likely that in certain circumstances and for certain items other cutoffs should be used, which also is suggested by Hui et al.\(^4\) Later on in the disease process, patients in our cohort seem to accept a higher symptom burden which endorses the findings of Dalal et al\(^5\) who found that patients with advanced disease reported to pursue a pain score of 3. By using different cutoffs depending on the situation and personal goals of the individual patient, a more person-centered approach may be achieved, improving shared decision-making\(^4\).

In conclusion, our results illustrate that the USD is a valid 12-item PROM containing the most prevalent symptoms in

---

**TABLE 7** Performance of different cutoff points for the USD items

| Cutoff point USD | ≥2 | ≥3 | ≥4 |
|------------------|----|----|----|
|                  | PPV (95%CI) | NPV (95%CI) | PPV (95%CI) | NPV (95%CI) | PPV (95%CI) | NPV (95%CI) |
| Pain             | 0.72 (0.68, 0.75) | 0.94 (0.92, 0.96) | 0.79 (0.75, 0.83) | 0.88 (0.86, 0.90) | 0.85 (0.81, 0.89) | 0.81 (0.78, 0.83) |
| Sleeping problems | 0.67 (0.63, 0.71) | 0.95 (0.93, 0.96) | 0.74 (0.70, 0.78) | 0.90 (0.87, 0.92) | 0.83 (0.79, 0.87) | 0.84 (0.81, 0.86) |
| Anorexia         | 0.52 (0.48, 0.57) | 0.90 (0.88, 0.92) | 0.59 (0.54, 0.63) | 0.89 (0.87, 0.91) | 0.64 (0.59, 0.69) | 0.87 (0.84, 0.89) |
| Abnormal stool   | 0.56 (0.52, 0.60) | 0.95 (0.93, 0.97) | 0.65 (0.60, 0.70) | 0.92 (0.90, 0.94) | 0.71 (0.66, 0.76) | 0.89 (0.87, 0.91) |
| Nausea           | 0.62 (0.56, 0.68) | 0.96 (0.95, 0.97) | 0.77 (0.70, 0.83) | 0.95 (0.93, 0.96) | 0.85 (0.77, 0.91) | 0.93 (0.91, 0.94) |
| Dyspnea          | 0.59 (0.52, 0.65) | 0.98 (0.97, 0.99) | 0.69 (0.61, 0.76) | 0.96 (0.95, 0.97) | 0.79 (0.71, 0.86) | 0.95 (0.93, 0.96) |
| Fatigue          | 0.77 (0.74, 0.80) | 0.93 (0.90, 0.95) | 0.83 (0.80, 0.86) | 0.84 (0.81, 0.87) | 0.89 (0.87, 0.92) | 0.75 (0.71, 0.78) |
| Anxiety          | 0.64 (0.60, 0.69) | 0.92 (0.90, 0.93) | 0.76 (0.71, 0.80) | 0.88 (0.86, 0.90) | 0.80 (0.75, 0.85) | 0.84 (0.81, 0.86) |
| Depressed mood   | 0.55 (0.50, 0.60) | 0.94 (0.92, 0.96) | 0.68 (0.62, 0.73) | 0.90 (0.88, 0.92) | 0.79 (0.73, 0.84) | 0.87 (0.85, 0.89) |

Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
cancer patients. The USD has proven content, criterion and construct validity and can detect clinically important symptom changes over time in both in- and outpatient groups through the whole continuum of cancer care. As a result the USD improves insight into symptom burden in the individual patient which is essential for comprehensive personalized care in daily oncology practice.

**CONFLICT OF INTEREST**

JK: advisory role Novartis (paid to institution). KS: advisory role Roche, Novartis, MSD, BMS, Pierre Fabre (all paid to institution). The other authors have no conflict of interest to declare.

**AUTHOR CONTRIBUTIONS**

FB, JK: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Validation—Verification, Visualization, Writing original draft. EN, ME: Conceptualization, Investigation, Validation—Verification. DZ, GH, SV, JV, EG, KS: Writing—review and editing. PW: Supervision, Writing—review and editing. AG: Conceptualization, Investigation, Methodology, Validation—Verification, Writing—review and editing. ST: Conceptualization, Investigation, Methodology, Resources, Validation—Verification, Supervision, Visualization.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ORCID**

Josephine J. Koldenhof https://orcid.org/0000-0003-4205-6611

**REFERENCES**

1. Nekolaichuk BCL, Maguire TO, Suarez-Almazor M, Rogers WT, Bruera E. Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. *J Clin Oncol*. 2019;17(11):3621–3630.
2. Strömgren AS, Groenvold M, Pedersen L, Olsen AK, Spile M, Sjögren P. Does the medical record cover the symptoms experienced by cancer patients receiving palliative Care? A comparison of the record and patient self-rating. *J Pain Symptom Manage*. 2001;21(3):189–196. https://doi.org/10.1016/S0885-3924(01)00264-0
3. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA*. 2017;318(2):197. https://doi.org/10.1001/jama.2017.7156
4. Richardson LA, Jones GW. A review of the reliability and validity of the Edmonton Symptom Assessment System. *Curr Oncol*. 2009;16(1):55.
5. Basch E. The rationale for collecting patient-reported symptoms during routine chemotherapy. *Am Soc Clin Oncol Educ Book*. Published online. 2014;161–165. https://doi.org/10.14694/EdBook_AM.2014.34.161
6. Hermansen-Kobulnicky CJ, Purtzer MA. “How i kept track of it of course was my business”: cancer patient self-monitoring as self-styled work. *Palliat Support Care*. 2014;12(5):355–361. https://doi.org/10.1017/S1478951513000308
7. Hersh EM, Del Vecchio M, Brown MP, et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. *Ann Oncol Off J Eur Soc Med Oncol*. 2015;26(11):2267–2274. https://doi.org/10.1093/annonc/mdv324
8. Homsi J, Walsh D, Rivera N, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. *Support Care Cancer*. 2006;14(5):444–453. https://doi.org/10.1007/s00520-005-0009-2
9. Barbera L, Sutradhar R, Howell D, et al. Does routine symptom screening with ESAS decrease ED visits in breast cancer patients undergoing adjuvant chemotherapy? *Supportive Care Cancer*. 2015;23(10):3025–3032.
10. Sutradhar R, Atzema C, Seow H, Earle C, Porter J, Barbera L. Repeated assessments of symptom severity improve predictions for risk of death among patients with cancer. *J Pain Symptom Manage*. 2014;48(6):1041–1049. https://doi.org/10.1016/j.jpain.2014.02.012
11. Bruera E, Kuehn N, Miller MJ, Selsmper P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. *J Palliat Care*. 1991;7(2):6–9.
12. Hui D, Bruera E. The edmonton symptom assessment system 25 years later: past, present and future developments. *J Pain Symptom Manage*. 2015;53(3):630–643.
13. Nekolaichuk C, Watanabe S, Beaumont C. The Edmonton Symptom Assessment System: a 15-year retrospective review of validation studies (1991–2006). *Palliat Med*. 2008;22(2):111–122. https://doi.org/10.1177/0269216307087659
14. Boddart M, Douma J, Dijkstra B, Bijkerk M. Netherlands quality framework. Published 2017. Accessed August 9, 2019. https://shop.iknl.nl/shop/netherlands-quality-framework-for-palliative-care/238613.
15. Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. *Supportive Care Cancer*. 2015;23(10):3025–3032.
16. Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the distress thermometer. *Cancer*. 2008;113(4):870–878. https://doi.org/10.1002/cncr.23622
17. Richtlijn Detecteren behoefte psychosociale zorg. Published 2017. Accessed February 5, 2018. https://www.oncoline.nl/detecteren-behoefte-psychosociale-zorg.
18. Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the distress thermometer. *Cancer*. 2008;113(4):870–878. https://doi.org/10.1002/cncr.23622
19. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study group: reaching international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported. *J Clin Epidemiol*. 2010;63:737–745. https://doi.org/10.1016/j.jclinepi.2010.02.006
20. Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. *Qual Life Res.* 2018;27(5):1159–1170. https://doi.org/10.1007/s11136-018-1829-0

21. R Core Team. (2018). The R Project for Statistical Computing. https://www.r-project.org/. Accessed September 14, 2019.

22. Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol.* 2007;60(1):34–42. https://doi.org/10.1016/j.jclinepi.2006.03.012

23. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics.* 2011;12(1):77. https://doi.org/10.1186/1471-2105-12-77

24. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. *J Pain Symptom Manage.* 2006;31(1):58–69. https://doi.org/10.1016/j.jpainsymman.2005.06.007

25. Faculty of Pain Medicine. Side Effects of Opioids. https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware/clinical-use-of-opioids/opioid-side-effects. Accessed August 12, 2019.

26. Raber-Durlacher JE, Brennan MT, Verdonck-de Leeuw IM, et al. Swallowing dysfunction in cancer patients. *Support Care Cancer.* 2012;20(3):433–443. https://doi.org/10.1007/s00520-011-1342-2

27. Katz N. The impact of pain management on quality of life. *J Pain Symptom Manage.* 2002;24(SUPPL. 1):38–47. https://doi.org/10.1016/S0885-3924(02)00411-6

28. Yamaguchi T, Morita T, Nitto A, et al. Establishing cutoff points for defining symptom severity using the edmonton symptom assessment system-revised Japanese version. *J Pain Symptom Manage.* 2016;51(2):292–297. https://doi.org/10.1016/j.jpainsymman.2015.09.011

29. Oldenmenger WH, De Raaf PJ, De Klerk C, Van Der Rijt CCD. Cut points on 0–10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: A systematic review. *J Pain Symptom Manage.* 2013;45(6):1083–1093. https://doi.org/10.1016/j.jpainsymman.2012.06.007

30. Kako J, Kobayashi M, Kanno Y, Miura T, Matsumoto Y. optimalcutofESASr.pdf. *Am J Hosp Palliat Med.* 2018;35(11):1390–1393. https://doi.org/10.1177/10499909118775660

31. Koldenhoj JJ, Witteveen PO, de Vos R, et al. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions. *Support Care Cancer.* 2014;22(9):2371–2380. https://doi.org/10.1007/s00520-014-2223-2

32. Koldenhoj JJ, Lankheet NAG, Steeghs N, Tennissen SCCM, Witteveen PO. Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study. *Support Care Cancer.* Published online. 2018;26(8):2641–2650.

33. Koldenhoj JJ, Langenberg MHG, Witteveen PO, Tennissen SCCM. Patient-reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: a retrospective, descriptive cohort study. *Eur J Cancer Care (Engl).* 2018;27(2):e12800.

34. Walke LM, Byers AL, Gallo WT, Endrass J, Fried TR. The association of symptoms with health outcomes in chronically Ill adults. *J Pain Symptom Manage.* 2007;33(1):58–66. https://doi.org/10.1016/j.jpainsymman.2006.07.013

35. Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. *Ann Surg Oncol.* 2007;14(8):2348–2357. https://doi.org/10.1245/s10434-007-9370-3

36. Salminen E, Clemens KE, Syrjänen K, Salmenoja H. Needs of developing the skills of palliative care at the oncology ward: an audit of symptoms among 203 consecutive cancer patients in Finland. *Support Care Cancer.* 2008;16(1):3–8. https://doi.org/10.1007/s00520-007-0252-9

37. Hannon B, Dyck M, Pope A, et al. Modified Edmonton Symptom Assessment System including constipation and sleep: validation in outpatients with cancer. *J Pain Symptom Manage.* 2015;49(5):945–952. https://doi.org/10.1016/j.jpainsymman.2014.10.013

38. Cleeton CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. *Cancer.* 2000;89(7):1634–1646. https://doi.org/10.1002/1097-0142(20000101)89:7<1634:AID-CNCR29>3.0.CO;2-V

39. Hui D, Dos Santos R, Chisholm GB, Bruera E. Symptom expression in the last seven days of life among cancer patients admitted to acute palliative care units. *J Pain Symptom Manage.* 2015;50(4):488–494. https://doi.org/10.1016/j.jpainsymman.2014.09.003

40. Philip J, Smith WB, Craft P, Lickiss N. Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. *Support Care Cancer.* 1998;6(6):539–541. https://doi.org/10.1007/s005200050212

41. Moro C, Brunelli C, Miccinesi G, et al. Edmonton symptom assessment scale: Italian validation in two palliative care settings. *Support Care Cancer.* 2006;14(1):30–37. https://doi.org/10.1007/s00520-005-0834-3

42. Claessens P, Menten J, Schotsmans P, Broeckaert B. Development and validation of a modified version of the Edmonton Symptom Assessment Scale in a Flemish palliative care population. *Am J Hosp Palliat Med.* 2011;28(7):475–482. https://doi.org/10.1177/1049909111400724

43. Chow E, Fan G, Hadi S, Filipczak L. Symptom clusters in cancer patients with bone metastases. *Support Care Cancer.* 2007;15(9):1035–1043. https://doi.org/10.1007/s00520-007-0241-z

44. Chang VT, Hwang SS, Feuerman M, Kasimis BS. Symptom and quality of life survey of medical a role for symptom assessment. *Cancer.* 2000;88(5):1175–1183.

45. Paiva CE, Manfredini LL, Paiva BSR, Hui D, Bruera E. The Brazilian version of the Edmonton Symptom Assessment System (ESAS) is a feasible, valid and reliable instrument for the measurement of symptoms in advanced cancer patients. *Support Care Cancer.* 2006;14(7):39–46. https://doi.org/10.1007/s00520-005-0834-3

46. Paiva CE, Manfredini LL, Paiva BSR, Hui D, Bruera E. The Brazilian version of the Edmonton Symptom Assessment System (ESAS) is a feasible, valid and reliable instrument for the measurement of symptoms in advanced cancer patients. *Support Care Cancer.* 2006;14(7):39–46. https://doi.org/10.1007/s00520-005-0834-3

47. Hui D, Shamieh O, Paiva CE, et al. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: a prospective, multicenter study. *Cancer.* 2015;121(17):3027–3035. https://doi.org/10.1002/cncr.29437

48. Seow H, Sussman J, Martelli-Reid L, Pond G, Bainbridge D. Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. *J Oncol Pract.* 2012;8(6):e142–e148. https://doi.org/10.1200/jop.2011.000525

49. Selby D, Cascella A, Gardiner K, et al. A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. *J Pain Symptom Manage.* 2010;39(2):241–249. https://doi.org/10.1016/j.jpainsymman.2009.06.010
49. Hui D, Park M, Shamieh O, et al. Personalized symptom goals and response in patients with advanced cancer. *Cancer*. 2016;122(11):1774–1781. https://doi.org/10.1002/cncr.29970

50. Dalal S, Hui D, Nguyen L, et al. Achievement of personalized pain goal in cancer patients referred to a supportive care clinic at a comprehensive cancer center. *Cancer*. 2012;118(15):3869–3877. https://doi.org/10.1002/cncr.26694

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** van der Baan FH, Koldenhof JJ, de Nijs EJ, et al. Validation of the Dutch version of the Edmonton Symptom Assessment System. *Cancer Med*. 2020;9:6111–6121. https://doi.org/10.1002/cam4.3253